Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies
2.7.2026 11:00:00 CEST | Business Wire | Press Release
Besins Healthcare, a global pharmaceutical company specializing in hormonal health, today announced the acquisition of UniD Manufacturing, a Belgium-based pharmaceutical development and manufacturing company with more than 20 years of recognized expertise in long-acting drug delivery technologies.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701779777/en/
Besins Healthcare Strengthens Innovation Capabilities with Acquisition of UniD Manufacturing, a Specialist in Long-Acting Drug Delivery Technologies
This acquisition brings together two highly compatible areas. Besins Healthcare brings deep expertise in hormone therapies for women’s and men’s health, including treatments such as Estrogel®/Oestrogel® (estradiol)2 and Utrogestan®3 (micronized progesterone) for women, and Androgel®/Testogel®4 (testosterone) for men. UniD contributes advanced capabilities in technologies that can enable more differentiated, less frequently administered treatment approaches.
UniD is one of very few companies worldwide that work with the advanced polymer technology used in the development and manufacture of complex long-acting delivery systems, such as implants and vaginal rings.1
Besins Healthcare will acquire the UniD site located in Seraing, Belgium, and 52highly skilled professionals will transfer to the company. As part of this new chapter, UniD Manufacturing will be renamed Besins Healthcare PharmTech and will progressively become a center of excellence dedicated to innovation and future development projects. In the immediate term, UniD will continue to operate as usual and serve its current clients with the same professionalism and commitment.
“This acquisition unites two teams with deep and complementary expertise, and we couldn't be more pleased to welcome UniD to Besins Healthcare," said Nicolas and Alexandre Besins, Co-CEOs, Besins Healthcare. "This is a natural partnership for both companies, and we are excited about what lies ahead."
"We are proud of what the UniD team has built over the past 20 years, and we are delighted to see those capabilities take on a new dimension as part of Besins Healthcare," said Marc Foidart, Executive Chairman at UniD Manufacturing, who will step down from his role. "The UniD team looks forward to innovating further with Besins Healthcare, as well as continuing to serve our existing clients with the same commitment they have always received."
Over the last 10 years, Besins Healthcare has experienced sustained, double-digit growth, with revenues reaching over €700 million in 2025, continuing a trajectory that has established the company as one of the fastest-growing companies in the hormonal health sector.5
UniD Manufacturing’s Headquarters in Seraing, Belgium
About UniD Manufacturing
UniD Manufacturing is a Belgium-based pharmaceutical CDMO specializing in long-acting drug delivery technologies and advanced polymer-based pharmaceutical formulations. The company provides development and manufacturing services for complex therapeutic products, such as implants, inserts, and vaginal ring technologies, supporting pharmaceutical and biotechnology partners from development through commercial supply. www.unid-manufacturing.com
About Besins Healthcare
Besins Healthcare is a global leader and specialist in hormonal health, and the only company in the world offering a complete portfolio of bioidentical hormones – progesterone, estradiol and testosterone – for both women and men. A family-owned business with more than five generations of heritage, the company sells its medicines across 114 countries through 22 wholly owned subsidiaries.5 In 2025, Besins Healthcare reported revenues of over €700 million.5 Estrogel®, Utrogestan®, Androgel®, Testogel® are trademarks owned by Besins Healthcare. www.besins-healthcare.com.
1 We are UniD. Available at https://www.unid-manufacturing.com/. Last accessed June 2026
2 Oestrogel Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/353/smpc#gref. Last accessed June 2026.
3 Utrogestan 100mg capsules. Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/352/smpc#gref Last accessed June 2026.
4 Testogel®. Summary of product characteristics. Available at: https://www.medicines.org.uk/emc/product/8919/smpc. Last accessed June 2026.
5 Data on file.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260701779777/en/
Contacts
Media contact: Sébastien Grilli, sgrilli@besins-healthcare.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange2.7.2026 16:47:00 CEST | Press Release
IQM Quantum Computers (Nasdaq: IQMX) (“IQM”, “IQM Quantum Computers” or the “Company”), a global leader in full-stack superconducting quantum computers, today became a publicly traded company following the completion of its business combination with Real Asset Acquisition Corp. (“RAAQ”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702960460/en/ IQM Quantum Computers Becomes First European Quantum Computing Company Listed on a Major U.S. Exchange The company’s American Depositary Shares begin trading today on the Nasdaq Global Select Market under the ticker symbol “IQMX”. The listing marks a major milestone for IQM establishing the company as the first European quantum computing company listed on a major U.S. stock exchange. Due to the proceeds of the transaction, IQM maintains a strong pro forma cash position of EUR 337 million. IQM enters the public markets with strong commercial momentum and a rapidly expanding globa
GigaDevice Launches First GD24CL Series I²C EEPROM, Further Expanding Its Non-Volatile Memory Portfolio2.7.2026 16:00:00 CEST | Press Release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, announced today the launch of its new GD24CL series I²C EEPROM. The series delivers outstanding performance, comprehensive security protection mechanisms, and excellent reliability that addresses the stringent requirements for stable and long-term storage of critical configuration data. These offered features will benefit applications in industrial, energy, Internet-of-Things (IoT), data centers, and networking. As GigaDevice’s first EEPROM product series, the launch further enhances the company’s non-volatile memory portfolio and provides customers with more dynamic storage solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260702394554/en/ GigaDevice Launches First GD24CL Series I²C EEPROM, Further Expanding Its Non-Volatile Memory Portfolio. The GD24CL series is designed with high
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur ® Peripheral Retrievable Scaffold System in a Select CLTI Cohort2.7.2026 13:00:00 CEST | Press Release
Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported by a grant, investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701995624/en/ The study investigates early vessel recoil following below-the-knee treatment using the Spur® Peripheral Retrievable Scaffold System in combination with a commercially available drug-coated balloon. The study plans to enroll up to 40 patients with chronic limb-threatening ischemia (CLTI) across two distinct cohorts: patients with diabetes and patients with end-stage renal disease receiving hemodialysis for at least six months, with women comprisi
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.7.2026 12:30:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to eight newly hired non-executive employees. The equity awards were granted on July 1, 2026 and consisted of options to purchase an aggregate of 63,685 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 30,300 shares. The options have an exercise price per share equal to $13.29, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted sh
Infobip Launches PitchMate — An AI Fan Companion for Global Football2.7.2026 12:00:00 CEST | Press Release
Global AI-first cloud communications platform Infobip launched PitchMate, a new AI-powered conversational agent that brings football fans closer to the action of the world’s biggest football tournament. Purpose-built for the global football audience, PitchMate joins the TGR Haas F1 Team RaceMate — Infobip’s AI fan engagement solution for the TGR Haas F1 Team — in demonstrating how conversational AI is transforming fan engagement across sports worldwide. RaceMate, launched last April for this year’s motorsport season, is an AI agent on WhatsApp and Apple Messages for Business that puts TGR Haas F1 Team fans at the center of the action. It delivers real-time race data, personalized content, team radio highlights, trivia, and native multilingual support, turning passive viewers into active participants through natural, human-like conversations across every race weekend. Since its launch, RaceMate has reached users in more than 60 countries, achieving more than 40,000 messages exchanged wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom